You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023218021
Dec 20237809
Jan 20244303
Feb 20244403
Mar 202410606
Apr 20248005
May 202411805
Jun 2024143019
Jul 202414003
Aug 202414204
Sep 202411203
Oct 20249803
Nov 202412008
Dec 20246607
Jan 2025164015
Feb 20253805
Mar 2025006
Apr 2025108
May 2025007
Jun 2025102
Total17120142